DATASHEET
Host:
Rabbit
Target Protein:
FZD3/Frizzled 3
Immunogen Range:
121-220/666
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
7976
Swiss Prot:
Q9NPG1
Source:
KLH conjugated synthetic peptide derived from human FZD3/Frizzled 3
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Background:
Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues.
PRODUCT SPECIFIC PUBLICATIONS
- Su, Lin, et al. "Deregulation of the planar cell polarity genes CELSR3 and FZD3 in Hirschsprung disease." Experimental and Molecular Pathology(2016).Read more>>
VALIDATION IMAGES
Lane 1: mouse pancreas lysate probed with Rabbit Anti-FZD3/Frizzled 3 Polyclonal Antibody, Unconjugated (bs-13239R) at 1:300 overnight at 4˚C. Followed by conjugation to secondary antibody (bs-0295G-HRP) at 1:5000 for 90 min at RT.
Formalin-fixed and paraffin embedded rat brain labeled with Rabbit Anti-FZD3/Frizzled 3 Polyclonal Antibody, Unconjugated (bs-13239R) at 1:200 followed by conjugation to the secondary antibody and DAB staining\n
Lane 1: Human SW480 cell Lysates; Lane 2: Human U-2 OS cell Lysates; Lane 3: Human A431 cell Lysates; Lane 4: Human SH-SY5Y cell Lysates. Probed with FZD3 polyclonal Antibody, unconjugated (bs-13239R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.